Opioid Management: Controlled Substance Prescribing, Assessment of Risk and Proper Patient Selection
Release Date: February 10, 2012
Expiration Date: February 10, 2013
Expected time to complete this activity as designed: 90 minutes
There are no fees for participating in or receiving credit for this online activity.
Opioids can be a successful treatment option for chronic, nonmalignant pain, but may not be well tolerated by some patients. Treatment failures occur for various reasons, including opioid-related adverse events, analgesic tolerance, hyperalgesia, comorbid mental disorders, opioid misuse to seek reward, and addiction. Assessing a patient’s suitability for opioid therapy can increase chances for successful outcomes and alert clinicians to the need to modify a therapeutic course if opioid therapy becomes ineffective or harmful.
This activity is designed for nurses who have an interest in enhancing their clinical skills in pain management.
Upon completion of this educational activity, participants should be able to:
- List the factors that need to be included in a comprehensive assessment of patients with chronic pain
- Recognize those chronic pain patients in your practice who would most likely benefit from opioid therapy based on assessment of potential risks and benefits
- Outline monitoring techniques proportionate to the individual patient’s risk for abuse
- Define components of safe prescribing from opioid trial to long-term management
- Summarize prevalence and types of opiate misuse, abuse, and diversion in your clinical practice setting
- Identify screening tools currently available to assess the risk of abuse, misuse, and addiction of prescribed opioid medications and documentation strategies to meet best practice standards
- Describe common concerns arising when prescribing opioid management for chronic pain
- Identify appropriate patient assessment methodology and incorporate strategies for structuring treatment based on patient assessment and monitoring
Controlled Substance Prescribing and Proper Patient Selection – Jeffrey A. Gudin, MD
Refining the Art of Risk Assessment in the Patient with Chronic Pain: The Key to Establishing a Risk Averse Practice – Steven D. Passik, PhD
Strategies to Improve Success in Opioid Management – Jeffrey A. Gudin, MD (Moderator) and Neil S. Skolnik, MD
Instructions for Participation and Credit
This activity is eligible for credit through February 10, 2013. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Jeffrey A. Gudin, MD
Pain Management Center
Englewood Hospital and Medical Center
Englewood, New Jersey
Dr. Jeffrey A. Gudin received his medical degree from Albany Medical College in Albany, New York. Following a transitional internship in surgery, medicine, and anesthesiology at St. Barnabas Medical Center in Livingston, New Jersey, he completed a residency in anesthesiology at Yale University School of Medicine. He continued his training with an extended postdoctoral fellowship in pain medicine at the Yale Center for Pain Management, where he was actively involved in research and teaching. He is currently director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey, an affiliate of the Mount Sinai School of Medicine. Dr. Gudin is board certified in pain medicine and anesthesiology, and is board eligible in addiction medicine.
An active speaker in the field of pain management, Dr. Gudin has been interviewed on various television news channels, including CBS, and other national news networks. Dr. Gudin has also been quoted in The New York Times and various regional newspapers in New Jersey and Connecticut. His clinical and research focus includes pain management, regional anesthesia, and preemptive analgesia, as well as increasing clinician awareness of pain assessment and management.
Steven D. Passik, PhD
Professor of Psychiatry and Anesthesiology
Vanderbilt University Medical Center
Dr. Steven Passik received his doctorate in clinical psychology from the New School for Social Research in New York City, and was chief fellow in the psychiatry service at Memorial Sloan-Kettering Cancer Center. Currently he is professor of psychiatry and anesthesiology at Vanderbilt University Medical Center in Nashville, Tennessee.
In 1999, Dr. Passik was a faculty scholar for the SOROS Foundation’s Project on Death in America. He has served on the editorial board of the Journal of Pain and Symptom Management, and has been a reviewer for the Journal of Pharmaceutical Care in Pain and Symptom Control, Journal of Pain and Symptom Management, Psycho-Oncology, Agency for Health Care Policy and Research Cancer Pain Guidelines, Cancer Investigation, and Oncology. Dr. Passik has served as the president of the Indiana Cancer and AIDS Pain Initiative and as editor in chief of the National Cancer Institute’s PDQ Supportive Care Editorial Board. He is the author of more than 120 journal articles, 60 book chapters, and 59 abstracts.
Dr. Passik was recently named a Fellow of DIV 28 of APA (Psychopharmacology & Substance Abuse), awarded a MayDay Fund Pain & Society Fellowship, given the academy of psychosomatic medicine Visiting Professor Award, and the American Psycho-Oncology Excellence in Clinical Care Award where he also serves on the advisory board. In addition, he received the Elizabeth Narcessian Award for Outstanding Educational Achievements. He speaks nationally and internationally on pain, addiction and the pain/addiction interface.
Neil S. Skolnik, MD
Professor of Family and Community Medicine
Temple University School of Medicine
Family Residency Program
Abington Memorial Hospital
Dr. Neil Skolnik is the associate director of the Family Residency Program at Abington Memorial Hospital and professor of family and community medicine at Temple University School of Medicine, Jenkintown, Pennsylvania. He is a graduate of Union College and Emory University School of Medicine, and completed his residency at the Jefferson University Hospital in Philadelphia.
Dr. Skolnik has contributed extensively to both the medical and lay literature and has served as a reviewer for numerous publications including Annals of Internal Medicine, Journal of Family Practice, and Pediatrics. He wrote the book On the Ledge from his experiences working in a small inner city family medicine office. Dr. Skolnik is the editor for the Current Clinical Practice series of textbooks and is also the editor of Clinical Practice Guidelines for Primary Care, and Essential Infectious Disease Topics for Primary Care. In addition, he writes a monthly clinical guidelines column in Family Practice News, is editor-in-chief for Redi-Reference medical handbooks, and contributes to the development of handheld computer medical resources nationwide, including for the American Diabetes Association, the Centers for Disease Control and Prevention, and the Infectious Disease Society of America.
He regularly presents both regionally and nationally on a range of topics, including hypertension, diabetes, migraine headaches, dermatology, tobacco cessation, asthma, acne, handheld medical informatics and deep vein thrombosis/pulmonary embolus.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours Program Number: 12-309-278
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jeffrey Gudin has received honoraria related to speakers’ bureau activities from Cephalon, Inc., King Pharmaceuticals, Inc., Pfizer Inc., and Purdue Pharma L.P.
Dr. Steven Passik has received honoraria related to speakers’ bureau activities from Ameritox, Ltd.; Cephalon, Inc.; Covidien; Endo Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Purdue Pharma L.P.; PharmacoFore; Pfizer Inc.; and Quest Pharmaceuticals, Inc. He has received grant support related to research activities from Covidien.
Dr. Neil Skolnik has received honoraria related to speakers’ bureau activities from Purdue Pharma L.P.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, Bronwyn Boyes, PharmD, director, and Sheri Sturgis, chief operating officer, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Drs. Gudin, Passik, and Skolnik have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Gudin, Passik, and Skolnik have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by an independent educational grant from Cephalon, Inc.
©2012 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.